Drug intelligence / Profile preview

AMS-3

Development stage: Preclinical
Lead developer: ZIP Zinc Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AMS-3 is a preclinical monoclonal antibody developed by ZIP Zinc Therapeutics in collaboration with Cardiff University. It targets zinc transporter proteins (ZIP family) to inhibit zinc-dependent processes essential for tumor growth, survival, and metastasis. In preclinical studies using triple-negative breast cancer (TNBC) xenografts, AMS-3 demonstrated potent anti-tumor activity, resulting in a 97% reduction in tumor growth and complete tumor destruction in 40% of cases. The candidate is being developed for the treatment of various solid tumors, including breast, colon, prostate cancers, and melanoma.

Targets

SLC39A6 (Solute carrier family 39 member 6)

Beyond the preview

Go deeper on AMS-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMS-3.

Explore the full profile